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ABSTRACT: 
Dilated cardiomyopathy (DCM) frequently affects relatively young, economically and socially active adults, 
and is an important cause of heart failure and transplantation. DCM is a complex disease and its pathological 
architecture encounters many genetic determinants interacting with environmental factors. The old 
perspective that every pathogenic gene mutation would lead to a diseased heart, is now being replaced by 
the novel observation that the phenotype depends not only on the penetrance -malignancy of the mutated 
gene- but also on epigenetics, age, toxic factors, pregnancy and a diversity of acquired diseases. This review 
discusses how gene mutations will result in mutation-specific molecular alterations in the heart including 
increased mitochondrial oxidation (sarcomeric gene e.g. TTN), decreased calcium sensitivity (sarcomeric 
genes), fibrosis (e.g. LMNA and TTN) or inflammation.  Therefore, getting a complete picture of the DCM 
patient will include genomic data, molecular assessment by preference from cardiac samples, stratification 
according to co-morbidities, and phenotypic description. Those data will help to better guide the heart 
failure and anti-arrhythmic treatment, predict response to therapy, develop novel siRNA-based gene 
silencing for malignant gene mutations, or intervene with mutation-specific altered gene pathways in the 
heart. 
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DCM: AN OVERLAPPING PHENOTYPE FOR MULTIPLE CONDITIONS  
Dilated cardiomyopathy (DCM) encompasses etiologically heterogeneous myocardial disorders that are 
defined by the presence of left ventricular or biventricular dilation and depressed myocardial performance, 
in the absence of overloading (hypertension, valvular or congenital heart disease) or chronic ischemic 
conditions.1 Interactions between the genetic and non-genetic factors may influence the severity and the 
outcome of DCM cases, including heart failure, rhythmic disorders, stroke, and the need for cardiac 
transplantation.1 The early identification of the causative gene mutation or the acquired cause is an 
important step to implement pre-symptomatic interventions, as some gene mutations, e.g. LAMIN A/C or 
RBM20, are highly penetrant and can be pro-arrhythmogenic.1,2 In this review, we describe the most 
advanced scientific achievements on genetic and cellular defects, diagnostic assessment and future 
therapeutic perspectives for this heterogeneous disease. 
Modern epidemiological studies considering disease heterogeneity and variable clinical presentation are 
lacking regarding DCM, and it is now recognized that DCM prevalence was underestimated in the initial 
population studies.3-5  Based on heart failure prevalence, considering left ventricular (LV) dysfunction as a 
surrogate for DCM, and extrapolating data from hypertrophic cardiomyopathy (HCM), it is now admitted 
that DCM could be as prevalent as HCM and reach 1/250-500 in clinical practice.2 Also, in the European 
registry on cardiomyopathies, the DCM proportion was unexpectedly high (almost 40 % of all 
cardiomyopathies) supporting that DCM prevalence in Europe could be close to the one of HCM.6 Recent 
and reliable population data are required to strengthen this statement. Overall, the recognition of a complex 
architecture for DCM not only in terms of gene-environment interactions, but also regarding its clinical 
presentation (with early stages of the disease being now recognized and defined by the presence of 
hypokinetic and non-dilated cardiomyopathy, preceding overt dilatation and heart failure) has made of 
DCM the most common cardiomyopathy.2,7  
A positive familial history can be detected in up to 30 to 50 % of DCM cases,7 and a genetic determinant can 
be identified following a screen of more than 40 genes in up to 40 % of DCM cases.1,2,8 Sarcomeric, 
mitochondrial and neuromuscular disorders are frequent etiologies in the presence of a “familial” history, 
where additional acquired conditions like exposure to toxics, diabetes, arrhythmia, myocarditis and 
pregnancy also contribute to the phenotype and outcome. Often, genetic determinants increase the 
susceptibility or are modifying factors in the presence of an external cause for DCM. The overlap between a 
genetic disorder and acquired disease becomes more and more ambiguous (Figures 1 and 2), raising 
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complexity in the assessment of these patients, but also opening new avenues in understanding and treating 
this etiologically heterogeneous disease.  
 
1-THE TUNNEL PERSPECTIVE: DCM SEEN AS AN INHERITED CARDIAC CONDITION   
Familial DCM is genetically heterogeneous and generally inherited as a monogenic trait transmitted in a 
dominant negative fashion, with incomplete penetrance (Table 1).1,2,9,10 Autosomal recessive, X-linked 
inheritance and mitochondrial inheritance are less frequent.1,2,9,10  
Autosomal dominant forms of DCM are linked to variants in more than 40 genes encoding proteins with 
functions in cardiac muscle contraction and relaxation (Table 1). Although those variants have been 
associated with DCM, the pathogenic role in DCM remains uncertain for many of them.11  
Mutations in the TTN gene coding for titin, the giant protein functioning as a nano-spring, is perceived as 
the most common cause for DCM, although with incomplete penetrance and variable, often milder 
phenotypes.12,13 Importantly, TTN-truncating variants in the presence of acquired diseases may be related 
to more ventricular arrhythmias in 2 studies,14,15 enhanced cardiac fibrosis,14 reduced hypertrophy14 and 
pronounced alterations in cardiac mitochondrial function.14 Analysis in other cohorts is required to verify 
and better understand those novel phenotyping findings.  
RBM20, the regulator of TTN splicing, has also been described as a cause of familial DCM with approx. 
frequency of 2-3%.16,17 Outcome of RBM20 mutation carriers may be worse, with higher frequency of atrial 
fibrillation and progressive heart failure. Also, mutations in the LMNA gene (lamin A/C),18-21 in FLNC 
(filamin C),22  DES (desmin),23,24 PLN (phospholamban),25-27 and SCN5A1,28 have been identified as a 
malignant cause of DCM. These mutations are associated with a typical time-course of rhythm disturbances 
ranging from atrio-ventricular blocks (LMNA, DES, SCN5A) to supraventricular and ventricular malignant 
arrhythmias (LMNA, FLNC, PLN and SCN5A). Importantly, ventricular arrhythmias can precede systolic 
dysfunction conferring a risk of sudden cardiac death irrespective of LV dysfunction.1,18,29,30 This implicates 
the use of genetic information in sudden cardiac death  risk estimation, and careful stratification of 
arrhythmogenic risk in DCM patients. In the presence of easy to assess clinical factors, prophylactic 
defibrillator implantation should be considered for these patients.31,32 In summary, DCM patients with 
mutations in LMNA, PLN, RBM20, FLNC, DES or SCN5A are at risk for worse prognosis and/or a higher rate 
of malignant arrhythmia, the latter being the case in TTN-truncated variants,14,33,34 and creating an overlap 
with arrhythmogenic cardiomyopathy.  
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In DCM with recessive inheritance, the mutated genes encode the proteins cardiac troponin I3 (TNNI3), 
titin (TTN), desmoplakin (DSP), dolichol kinase (DOLK), GATA zinc finger domain-containing protein 1 
(GATAD1) and flavoprotein (SDHA). X-linked diseases associated with DCM include neuromuscular 
disorders (such as Becker and Duchenne muscular dystrophies). DCM occurs in both patients with 
mitochondrial diseases and inherited storage disorders (such as hemochromatosis) as the end-phenotype 
of early hypertrophic cardiomyopathy.7,35,36 Mitochondrial cardiomyopathies demonstrate clinical and 
genetic heterogeneity, with variable syndromic manifestations.  
Primary DCM patients with a positive family history for cardiomyopathies or with distinct hints for a genetic 
cause of the disease (red flags, e.g. conduction disease) should be offered the possibility of genetic testing 
and counseling.7,31,37,38 
 
1.1. Sarcomeric mutations and DCM: from the contractile apparatus to the dilated phenotype 
The sarcomere plays a central role in cardiomyocyte function and metabolism and the molecular link 
between sarcomeric mutations and the dilated phenotype has increasingly been elucidated. Mutations in 
beta-myosin heavy chain (bMHC) as well as in alpha-myosin heavy chains (aMHC) may cause familial 
hypertrophic cardiomyopathy (HCM) and DCM, with sometimes features of restrictive cardiomyopathy 
(RCM).39-42 Thin filament mutations have highlighted a key role for calcium-dependent tension in the 
disease phenotype: these mutations are only a small fraction (~5-10%) of all HCM mutations and often 
cause an increase in myofilament calcium sensitivity, while thin filament mutations associated with DCM 
frequently show reduced calcium sensitivity of myofilament force development (Figure 3).43 Hence, 
identification of the thin filament sarcomeric mutation, which causes the early contractile alteration, would 
predict the development of hypertrophic versus dilated cardiomyopathy. Importantly, sarcomeric gene 
mutations may disrupt the highly tuned balance between mechanical force generation and Ca2+-cycling 
dynamics. A recent study tried to differentiate thin filament mutations that alter calcium-dependent tension 
(increase or decrease) into the spectrum of hypertrophic versus dilated cardiomyopathy.43 Altering 
myofilament Ca2+ sensitivity in mice with specific TNNC1 gene variants resulted in the activation of both 
calcineurin and MEK1-ERK1/2 signaling in the presence of a variant which, increased calcium-sensitivity, 
resulting in concentric hypertrophy (Figure 3).43 In contrast, inhibition of MEK1-ERK occurred in the 
presence of a DCM-related variant, which reduced calcium-sensitivity and resulted in cell elongation, 
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suggesting that the combination of calcineurin activation and MEK1-ERK inhibition underlies the eccentric 
(dilated) remodeling. High-resolution structural information about multiprotein may help to characterize 
the baseline function and structure of the Tropomyosin overlap region of the thin filament, as mutations 
with differential phenotypes exert opposite effects on the Tropomyosin−Troponin overlap.44  
Increased myofilament Ca2+-sensitivity and improved cardiac contractility is also seen in a mutant 
tropomyosin (TM-E54K) mouse treated with a β-arrestin 2-biased ligand of the angiotensin II receptor.45 
The increase in myofilament Ca2+-sensitivity resulted from enhanced phosphorylation of myosin light 
chain-2.45  
The open question is how different defects in different proteins may cause a similar end-phenotype. Recent 
studies in human DCM samples demonstrated that a sarcomeric TNNI3 (troponin I) mutation impaired 
length-dependent activation (i.e. Frank-Starling mechanism), and a TNNT2 (troponin T) mutation increased 
passive stiffness, while a non-sarcomeric LMNA mutation did not cause direct sarcomere changes, but was 
associated with reduced force generation due to the disease-related cellular hypertrophy and reduced 
myofibril density.46 A basic integrated-tension index could be used to differentiate DCM from HCM and, as 
a consequence, to understand the phenotype and to choose the best pharmacologic treatment.43 
 
1.2 DCM, arrhythmogenic cardiomyopathy and channelopathies 
The electrical instability observed in some DCM cases creates a clinical overlap between DCM and 
arrhythmogenic cardiomyopathy and channelopathies. The above-mentioned LMNA mutations are 
associated with high-risk malignant ventricular arrhythmias, regardless of the severity of LV dysfunction 
and dilatation.38,47 Other genes linked to arrhythmogenic phenotypes in DCM are the gene encoding for 
filamin C (FLNC), 22 RBM20,16,17 phospholamban (PLN),25,26 and more recently TTN-truncating variants.14,15 
Also, mutations in genes for desmosomal proteins, which are usually associated to arrhythmogenic right 
ventricular cardiomyopathy (ARVC) have now emerged as a cause of  DCM with  a propensity to ventricular 
arrhythmia too.48-51  
 
Importantly, DCM may be caused also by genes encoding for/or modulating ion channels (i. e. PLN, RYR2 
and SCN5A)38 Indeed, mutations involving sodium, calcium and potassium related proteins support an 
alternative disease mechanism of dilation primarily triggered by dysfunction in electrical excitability rather 
than a structural defect.1,27,52 In particular, in familial DCM, missense mutations in SCN5A, that are also 
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linked to long QT and Brugada syndromes, carry a higher risk for arrhythmias.3 The different roles of SCN5A 
in the myocardium and the conduction system produce a combination of arrhythmia and cardiomyocyte 
dysfunction, as witnessed by transgenic-directed inducible expression of the F1759A mutation in the Scn5A 
gene that leads to atrial fibrillation and persistent sodium currents in atria and ventricles and reduced 
ejection fraction.1,53 
PLN mutations lead to variable phenotype with early onset DCM.25,54 In order to assess mechanisms and 
impact of these mutations, iPSCs with the R14del PLN mutation were generated.55 Aberrant Ca2+ handling 
after caffeine and abnormal Ca2+ transients, which could be reversed upon correction of the primary 
mutation by gene editing  could be described in these cells,55 while reduced developed force that could be 
improved after genetic correction was observed in 3-dimensional human cardiac tissue.56  
Although those variants have been associated with DCM, their pathogenic role in DCM has to be 
reconsidered, with many of them being represented as much in large population controls than in DCM 
cases.11  
 
1.3 Possible genetic basis and mechanisms of tachy-induced cardiomyopathy 
The development of cardiomyopathy due to arrhythmia may take months to years, but recurrent 
arrhythmia can lead to LV dysfunction and heart failure.57 Tachy-induced cardiomyopathy can also  be 
associated with genetic factors. Serum and glucocorticoid-regulated kinase 1 (SGK1) is a component of the 
cardiac phosphatidylinositol 3-kinase signaling pathway that has proarrhythmic effects linked to 
biochemical and functional changes in the Na+ channel. These effects can be reversed by the Late Na+ 
current inhibitor, ranolazine.58 Accordingly, inhibition of SGK1 in the heart protects against fibrosis, LV 
dysfunction, and Na+ channel alterations after hemodynamic stress.58 
Whether tachyarrhythmia unmasks a latent cardiomyopathy, or whether genetic factors can induce both 
arrhythmia and DCM is still under debate. Recent advances in our understanding of channelopathies and 
the co-existence of arrhythmic and dilated phenotypes in some patients seems to foster this theory.28,59,60 
Mutations in the cardiac Na+ channel and in the ryanodine receptor can lead to arrhythmia, but also to LV 
dysfunction.57,60 
 
1.4. Mitochondrial dysfunction in the complex road to dilated cardiomyopathies 
Mitochondrial cardiomyopathy is a part of a heterogeneous group of multisystemic diseases that develop 
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as a consequence to mutations in nuclear or mitochondrial genes.61 Inheritance follows matrilineal rule for 
mtDNA mutations and Mendelian rules for nuclear gene defects.62 The cardiac phenotype is characterized 
by LV hypertrophy that commonly evolves through LV dilation and dysfunction.63 A typical example of DCM 
associated with nuclear gene defects is Barth Syndrome (BTHS), an X-linked recessive disorder 
characterized by left ventricular non-compaction (LVNC) cardiomyopathy, skeletal myopathy, neutropenia, 
growth retardation, and 3-methylglutaconic acidurea.64 BTHS is caused by mutations in the TAFAZZIN (TAZ) 
gene that lead to a defective phospholipid transacylase, termed tafazzin. Defective tafazzin activity leads to 
alterations in the content and composition of cardiolipin and the appearance of monolysocardiolipin.65,66 
mtDNA defects may range from large rearrangements (deletions) of the mtDNA to point mutations67-69, that 
prevalently affect OXPHOS complexes. Moreover, a defective mtDNA repair system is evident in DCM human 
hearts, which is accompanied by activation of PGC-1α, abnormal mitogenesis, and increase in mtDNA 
deletion mutations.70 This maladaptive compensatory response further contributes to the progression of 
the disease.  
mtDNA alterations are common in human populations71 and often lead to the replacement of amino acid 
residues without pathological significance. When affecting evolutionarily conserved residues, 
mitochondrial protein synthesis and specific respiratory enzyme activities mtDNA mutations can have 
pathogenic significance.69 Defects in the mechanism of mtDNA repair can promote accumulation of mtDNA 
defects with wide variability in the age of onset and severity of the phenotype.72 It is also needed to consider 
that nuclear genes, which further increase the complexity of the phenotypic effects of the gene-to-gene 
interactions, control mechanisms of mtDNA repair. Genetic mutations disturbing mitochondria dynamics 
are responsible for neurodegenerative conditions and cardiac failure.73,74 Thus, defects involving the 
complex machinery of mitochondria repair/replacement can promote mtDNA defects and facilitate the 
occurrence of cardiac dysfunction. These considerations might be relevant in specific environmental 
contexts, for example in presence chronic exposure to the very low dose of ionizing radiation for 
occupational or health purpose (Figure 4).75,76 Epigenetic or inherited defects in mitochondria dynamic 
and/or function, in particular, those with low penetrance and expressivity can lead to a cardiac phenotype 
when interacting with a specific environment, which may explain the sizeable phenotypic variability of 
mitochondrial cardiomyopathy.  
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1.5 DCM and primary restrictive cardiomyopathy 
A broad overlap exists between cardiomyopathies and for some genes clinical presentation ranges from 
DCM to HCM, arrhythmogenic or restrictive cardiomyopathy, with sometimes features of non-compaction. 
Restrictive cardiomyopathy (RCM) is a rare disorder characterized by increased cardiac filling pressure 
related to enhanced wall stiffness, leading to severe atrial dilatation, despite a limited increase in cardiac 
chamber dimensions and wall thickness.77,78  RCM is seen in primary myocardial disease, in infiltrative 
disorders, or can be associated with autoimmune diseases or metabolic disorders.77,78  
Sarcomeric proteins play a central role in controlling myocardial tension and relaxation, and calcium-
sensitivity is a key player in controlling this equilibrium (section 1.1).43 In a series of 1226 HCM patients, 
2,3 % had a restrictive phenotype, with on half of the RCM probands having mutations in MYH7 or TNNI3 
genes.42 Underlying this phenotypical overlap, previous linkage analysis have revealed that TNNI3 
mutations, a gene involved in HCM and DCM, are also associated with RCM,79 and further analysis 
confirmed the role of TNNI3 in RCM.80,81 Cardiomyocytes of cTnI R193H mice showed shortened cell 
length and impaired relaxation.82 Multiple phenotypes ranging from RCM, HCM and DCM were also 
observed in the same family in the presence of a I79N TNNT2 mutation.83 Reconsidering the old view that 
DCM presentation could be the end-stage presentation of several cardiac diseases, those results support a 
genetic base for overlapping phenotypes.  
Another example of phenotypical overlap is given by non-sarcomeric genes. Variants in TTN, DES, FLNC 
and MYOPALLADIN (MPN) are also related to DCM, HCM and RCM.78  Desmin accumulation leads to clinical 
phenotypes affecting peripheral and/or cardiac muscles, with sometimes predominant cardiac or 
peripheral involvement.24 Altering cellular trafficking, cardiac desminopathy can present as DCM, HCM, or 
RCM with frequent involvement of the conduction system leading to AV blocks.23 Other genes linked to 
rhythmic disorders in DCM including FLNC, RBM20, PLN, and TTN are also associated with RCM,77,84 
supporting the existence of a genetic base for this phenotypic continuum between cardiomyopathies.  
Iron overload cardiomyopathy (IOC) usually presents with a myocardial concentric or asymmetric 
nonextreme hypertrophy with progressive left ventricular remodeling and dysfunction.85 After an 
asymptomatic period, patients with in IOC present with mild heart failure symptoms, because of 
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restrictive physiology and may mimic heart failure with preserved ejection fraction. Later, ejection 
fraction regresses with the presence of end-stage heart failure.86 
 
1.6 From genes to clinical tools: the noisy background in DCM genetics  
The development of population genetics databases like the Exome Aggregation Consortium (ExAC) and the 
Genome Aggregation Database (gnomAD) have offered an unprecedented view of rare variation in the 
human genome.87 These resources have revealed that the frequency of rare variation in many genes is much 
higher than hitherto appreciated, which has implications for variants and genes that have been previously 
associated with disease. A substantial proportion of variants reported as causative for DCM and other 
cardiomyopathies are present in these (clinically uncontrolled) population databases.88,89 Comparing the 
total burden of rare variation in genes associated with DCM between ExAC and large cohorts of DCM cases 
has revealed that a significant excess in cases is observed in only a small number of well characterized DCM 
genes such as TTN, LMNA and the sarcomeric genes.11 These findings suggest that the pleiotropic effects of 
variants associated with cardiac disease and the genetic overlap between DCM and other inherited cardiac 
conditions may have been overestimated.  
The lack of an overall case excess does not necessarily preclude a role in DCM.  In fact, pathogenic variants 
can be restricted to specific residues or small domains and therefore masked by the background benign 
variation in the rest of the gene, e.g. the DCM mutation hotspot found in the titin splicing regulator RBM20.90 
However, aside from founder mutations (such as the PLN R14del in 10-15% of DCM patients in the 
Netherlands),26 variants in genes without a case excess are likely at best to be rarely causative in DCM. In 
order to reduce the uncertainty associated with standard clinical genetic testing, and the danger of false 
positive results, panels should be restricted to genes with strong evidence of pathogenicity. Initiatives such 
as ClinGen have been established to curate these gene to disease associations and identify panels of 
validated and interpretable genes for clinical genetic testing.91 However, as shown by a recent study 
assessing the evidence for genes implicated in hypertrophic cardiomyopathy,92 it is likely that genes with 
an excess of rare variants in case series will account for the vast majority of pathogenic variants detected in 
patients. This could be explained by a higher frequency of HCM, and a smaller proportion of asymptomatic 
mutation carriers in HCM as compared to DCM.  
The extent of rare benign variation in the population is particularly prevalent for interpreting missense 
variants, particularly in genes that were implicated in DCM based on limited evidence and are regularly 
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included in clinical panels (such as MYBPC3 and MYH6).11,93 Truncating variants in several different genes 
have now been shown to be key determinants in DCM genetics and have been validated through burden 
testing between cases and controls (for TTN,12,94 DSP11,93 and FLNC22) or segregation in large families 
(BAG395,96). Although variant interpretation guidelines produced by the American College of Medical 
Genetics (ACMG)97 deem a truncating variant as actionable if it is sufficiently rare and a loss of function 
mechanism has been proven for the affected gene in the disease being tested, such variants in novel or 
poorly characterized DCM genes should not be assumed to be pathogenic given that each individual is 
estimated to harbor at least 100 truncating variants, of which approximately 20 will be rare.87  
 
1.7 Deciphering missing heritability and incomplete penetrance in DCM 
Although restricting genetic testing to validated genes is a prudent strategy in the clinic, whole exome or 
genome sequencing of large patient cohorts and family pedigrees now offers the opportunity for the 
discovery of novel genetic factors underlying DCM. This may include protein-coding variation in novel 
genes, non-coding and regulatory variants affecting known DCM genes, and the assessment of oligogenic 
inheritance which has been hypothesized as possible mode of transmission in DCM, factors that may 
underlie the low penetrance of this disease1,7 Also the complex interaction between common and rare 
variation with other environmental and medical factors may be responsible for the clinically observed 
heterogeneity of DCM even in families carrying the same pathogenic variant. However, even when taking 
all knowledge about the impact of multiple high penetrance variants in single patients and common variants 
identified in GWA studies into account,98,99 there is still a large fraction of heritability and a considerable 
phenotypic variability that cannot be explained.100 The deciphering of epigenetic alterations could provide 
new clues to this obstacle: epigenetic changes can occur due to intrinsic and environmental factors and can, 
in variable degree, be transmitted to the progeny. Already during cardiac development, DNA methylation 
of gene bodies and post-translational modifications of histones of developmental and sarcomeric genes can 
be detected that also occur during heart failure.101-103 In DCM, a first study was able to map the genome-
wide DCM methylome and identify putative new players in its pathophysiology, such as LY75.104 In a recent 
study embarking on a multi-omics design including whole-genome sequencing, transcriptome sequencing 
and high-density DNA methylation profiling, Meder et al. could delineate a significant role of DNA 
methylation patterns on cardiac gene expression and DCM.105 They further raised a new paradigm, the 
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cross-tissue conservation of methylation alterations, rendering epigenetics a novel class of cardiac 
biomarkers and potential therapeutic target.106 
 
2-THE BROADER VIEW: DCM AS A PHENOTYPE AT THE INTERSECTION BETWEEN GENES AND 
AQUIRED CONDITIONS.  
2.1. Inflammation in genetic cardiomyopathy, viral infections and myocarditis: complex 
interactions  
In DCM, the pathogenicity of a gene mutation is modulated by interfering factors: besides age and hormonal 
context, inflammation (i.e. virus infection, cardiac inflammation, systemic disease), hypertension, 
mitochondrial alterations, as well as other environmental triggers (like toxic exposure) are strong 
candidates to modulate the expression of genetic determinants and the prognostic of the disease.12,74,75  
In particular, low grade chronic cardiac inflammation mediated by the innate immune system is often seen 
in genetic cardiomyopathies.107 Importantly, autoimmune diseases, viral infections or toxic stimuli that 
trigger innate immunity may increase heart inflammation in a subject with a “genetic” predisposition to 
cardiomyopathy, worsening the prognosis.108  
Not unfrequently, LV dysfunction can be caused by viral, bacterial, fungal, parasitic, rickettsial, and 
spirotricheal infections. In viral myocarditis, parvovirus B19, adenovirus, coxsackievirus B and other 
enteroviruses, influenza A, human herpes virus 6, cytomegalovirus, Epstein-Barr virus, herpes simplex 
virus type 1, and hepatitis C virus are the most common viruses identified by means of endomyocardial 
biopsies,109,110 with coxsackievirus being predominant in the 1980s, adenovirus in the 1990s, and 
parvovirus B19 since 2000.111 
TLRs are involved in early activation of the innate immune response against viruses and other infections. 
So far, specific roles in inflammatory cardiomyopathy and myocarditis have been described for TLR2, TLR3, 
TLR4, TLR7, and TLR9 along with their downstream adaptors MyD88 and TRIF.112-116 In particular, 
enteroviruses, activate TLR3 signaling: animals lacking TLR3 exhibit enhanced mortality after being 
infected with enteroviruses.117 Importantly, subjects affected by enteroviral myocarditis/cardiomyopathy 
present with a common TLR3 polymorphism.118 Upon viral infection, patients who develop myocarditis 
have elevated TLR4 transcripts, while TLR4 deficient mice had heart inflammation in CVB3 myocarditis.107  
On the other way, animal studies have shown that  gene mutations may trigger inflammation, independent 
of other acquired immune activators, but more studies are needed in order to confirm this hypothesis.107 In 
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the presence of myocardial derangements, such as the ones that occur in DCM, inflammation enhances 
fibrosis in the left ventricle and promotes fibrofatty degeneration in the right ventricle.107 Parallel to this, 
stimulation of the immune system will lead to the appearance of circulating cardiac auto-antibodies, which 
are potential therapeutic targets.107,119  Also, it is very likely that myocyte hypertrophy in DCM may act on 
macrophages via enhanced oxidative stress, that in turn favors further myocyte hypertrophy and fibrosis, 
hence letting cardiac disease to progress.107 
 
2.2 The genetic influence on development of toxic cardiomyopathies 
Alcohol and anthracyclines are well-known cardio-toxic triggers sharing the ability to induce a broad 
spectrum of cardiac impairments, going from asymptomatic cardiac remodeling and subclinical dysfunction 
to severe heart failure.120-122 Recent studies highlight the potential role of genetic factors interacting with 
toxic triggers and potentially contributing to the inter-individual variability of cardiac phenotype.123-127 
In alcoholic cardiomyopathy, alcohol metabolism and accumulation of its main metabolite, acetaldehyde, 
could contribute to the myocardial damage through alterations of sarcoplasmic reticulum, mitochondria, 
calcium transient and Ca2+ sensitivity of myofibrils, increased apoptosis, alterations in lipid energetic 
metabolism and protein synthesis, increased oxidative stress, activation of renin-angiotensin and 
sympathetic systems.120 SNPs in genes involved in ethanol metabolisms such as ADH1B (A/A), ALDH2 (A/G 
or A/A) and CYP2E1(T/C or T/T) increase genetic susceptibility to ethanol-induced cardiac dysfunction. In 
particular, fast ADH1B (A/A) induces a more rapid conversion of ethanol into acetaldehyde, whose 
degradation can be delayed due to the reduced enzyme activity of ALDH2 (A/G or A/A), and resulting in a 
toxic accumulation.  CYP2E1(T/C or T/T) further worsens the impairment of ethanol metabolism inducing 
greater accumulation of both acetaldehyde and ROS.123 
Anthracyclines cardiotoxicity (ACT) represents the most critical dose-limiting side effect of these wide-used 
antineoplastic drugs. Novel mechanisms of cardio-toxicity have been recently identified and explored in 
patients with malignancy treated with anthracyclines. First, anthracyclines can induce dsDNA break and 
cell death through reticence of Topoisomerase 2-beta (Top2β).121 The SNP Ser427Leu in RARG is highly 
associated with ACT since this variant alters the ability to downregulate Top2β transcription, leading to its 
accumulation in cardiomyocytes where it is targeted by anthracyclines.124 A potential role in the ACT might 
be played by the reduction of anthracyclines to cardiotoxic alcohol metabolites through carbonyl reductases 
(CBR). Indeed, individuals with CBR3 V244M homozygous G genotypes (CBR3 G/G) show a higher 
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cardiomyopathy risk, since this genetic variant increases synthesis of these metabolites.125 The ACT 
pathophysiology involves unbalancing between ROS generation and intrinsic antioxidant species. This leads 
to impairment of calcium homeostasis, mitochondrial bio-energetic disruption, activation of the ubiquitin-
proteasome system leading to sarcomeric structure dysregulation, activation of NFκB signaling and 
immune system, senescence of cardiac and endothelial progenitor cells (CPCs and EPCs).121 Anthracyclines 
accumulation within the cardiomyocytes is the essential step to determine their oxidative potential. 
Accordingly, many of the other SNPs associated with higher risk of the ACT are located in genes able to 
influence anthracycline pharmacokinetics (SLC28A3, SLC28A1, SLC10A2, ABCB1, ABCB4, ABCC1, 
UGT1A).126,128 Genetic susceptibility to ACT can also affect cardiac protective mechanisms. Indeed, the 
rs2232228 AA genotype in HAS3 gene reduces hyaluronan synthesis leading to inadequate tissue 
remodeling and insufficient protection of the heart from ROS-mediated injury.129 ACT also shows 
coexistence of two or more TNNT2 (cTNT) splicing variants, which lead to a temporally split myoﬁlament 
response to increasing Ca2+ concentrations and could decrease myocardial contractility.130 Individuals 
homozygous for the CELF4 rs1786814 G allele are more likely to coexpress the embryonic and adult TNNT2 
variants and, thus, to possibly enhance cardiotoxicity risk in response to anthracyclines.127 
Recently, a further mechanism of doxorubicin-mediated cardiotoxic effects has been identified based on the 
downregulation of the crucial circular RNA regulator Quaking.131 Doxorubicin leads to a significant 
downregulation of Quaking in the heart, thus making it more susceptible for cardiac apoptosis. In a 
therapeutic approach, AAV-mediated cardiac overexpression of Quaking rescued the heart from 
Doxorubicin-mediated toxicity thus presenting a potential future entry point of novel cardiac anti-toxic 
treatments.  
Antineoplastic drugs can also cause cardiomyopathy by an interference with the innate immune system.132 
In particular, toll-like-receptors (TLRs) can “sense” anthracycline-mediated damage, with TLR2 KO mice 
showing partially preserved cardiac function and improved survival compared to WT animals in a model of 
acute doxorubicin administration.107,133 Other TLRs exhibit a controversial behavior: for instance TLR4 KO 
mice showed protection from anthracycline-induced cardiac toxicity,134; while anti-TLR4 antibodies had 
opposite effects.107,135 
Of notice, the innate and adaptive immune system has a pivotal role in the recognition and elimination of 
tumor cells. One of the supposed mechanisms by which anthracyclines are effective in cancer is the 
stimulation of an antitumor immunity by inducing immunogenic cell death. This effect is achieved via innate 
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immune receptors, including TLR3 and 4.136 Intuitively, the immune system is involved also in cardiotoxicity 
developed after oncologic treatments with immune checkpoint inhibitors, that can cause, among other 
immune related adverse events, cardiac immune-related adverse effects such myocarditis and 
pericarditis.107,137,138 
 
2.3 Genetic predisposition to peripartum heart failure: what about hormones?  
Most genetic DCMs only become penetrant after puberty, indicating an hormonal change as a requirement 
to develop the phenotype. Peripartum cardiomyopathy (PPCM) is an example of interaction between 
hormonal changes and genetic predisposition. PPCM has been defined as "an idiopathic cardiomyopathy 
presenting with heart failure secondary to LV systolic dysfunction towards the end of pregnancy or in the 
months following delivery, where no other cause of heart failure is found”.139 PPCM is a severe complication 
of pregnancy with a high morbidity and mortality.140,141 Meanwhile it is considered more a syndrome with 
different underlying disorders. Among those, genetic forms of cardiomyopathy seem to account for some 
cases since for example the disease is more frequent in certain geographical regions, Africa (1 in 100 to 1 in 
1000 pregnancies) or Haiti (1 in 299 pregnancies), and since there are reports from PPCM patients with a 
clear family history of heart failure.142,143 Indeed, more recently, several studies discovered mutations 
associated with familial forms of DCM in PPCM patients, i.e. mutations in TTN, MYBPC3, MYH6, MYH7, PSEN2, 
SCN5A, TNNC1, and TNNT2.144-146 Beside the presence of mutations associated with familial forms of DCM 
in PPCM patients, it is also likely that additional mutations or polymorphism may be present in these 
patients and contribute to their susceptibility to peripartum heart failure. Extrinsic factors like viral 
infections could also mediate peripartum heart failure and it has been shown that virus including Epstein-
Barr virus, human cytomegalovirus, human herpes virus 6, and parvovirus B19 could be identified in up to 
30 % of cardiac samples in PPCM,147 but their exact pathogenic role still needs to be defined.148  
Interestingly, it seems that genetic and non-genetic forms of PPCM may merge on a common pathway 
including unbalanced oxidative stress and subsequent cleavage of the nursing hormone prolactin into an 
angiostatic fragment that initiates and drives progression of PPCM.140,141 This discovery led to a disease 
specific treatment concept combining heart failure treatment with the prolactin blocker bromocriptine 
(BR), which is named "the BOARD therapy regime" (BR, Oral heart failure drugs, Anticoagulation, Diuretics) 
for PPCM.149 
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Although current data suggest that patients with PPCM of different etiologies seem to profit from the 
BOARD therapy, epidemiological studies suggest that PPCM in women with a familial history of 
cardiomyopathies have a poorer prognosis—a feature that might affect risk stratification and clinical 
management of these patients.141 Therefore, further analysis of underlying pathophysiology is important 
for more personalized therapy regimes. Moreover, genetic counseling in patients with a family history of 
(peripartum) heart failure should be considered, which may contribute to a better understanding of the 
disease pathophysiology and for better and earlier treatment and management of relatives at risk.  
 
2.4 Metabolic triggers in DCM: Diabetes and DCM  
In diabetic patients, cardiovascular diseases represent a major cause of morbidity and mortality. In addition 
to increased coronary artery disease and hypertension, there is compelling evidence that diabetes has a 
direct negative effect on the heart,150 being an independent risk factor for heart failure even after adjusting 
for age, sex, race and hypertension.151-153 Mechanisms of such deleterious cardiac effects include 
mitochondrial dysfunction, oxidative stress, shift in energetic substrate utilization (increase in fatty acid 
oxidation and decrease in glucose metabolism), disturbed calcium homeostasis, and neurohumoral 
activation.150,154  
Among the described gene mutations associated with DCM, mutations in LMNA gene, encoding nuclear 
intermediate filament proteins lamins A/C, more specifically the variant p.G602S was recently associated 
with type 2 diabetes.155 Further molecular and physiological studies regarding this variant are needed to 
understand its predictive value in DCM.155 Taken into consideration the increasing prevalence of diabetes, 
as well as its associated complications, an analysis of the correlation between genotypic and phenotypic 
patient characteristics deserves further investigations, intending to establish a disease-gene mutation 
association and apply an early intervention in disease progression.  Therefore, the presence of diabetes –as 
well as hypertension or other metabolic conditions should be included in the patient phenotyping, and in 
order to assess gene-environmental interactions in DCM. 
 
3-HOW CAN IMAGING HELP IN DCM PHENOTYPING? 
Echocardiography remains the cornerstone for routine and quick assessment left ventricular function in 
DCM patients. In addition to confirming the clinical diagnosis, routine echocardiography provides 
additional prognostic information such as the severity of ventricular dysfunction, the presence of any 
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concurrent valvular disease and the pulmonary artery.156 More sophisticated echocardiography reliant on 
tissue deformation parameters may provide additional risks stratification and/or prognostic information, 
such as global longitudinal strain, circumferential and radial strain.157 Those parameters will help clinicians 
in deciphering the disease heterogeneity associated with DCM.   
Cardiac magnetic resonance imaging (CMR) is currently embedded in routine clinical practice with respect 
to follow-up assessment of left ventricular volumes and accurate ejection fraction, due to its high 
reproducibility and accuracy.115,116 CMR provides information on tissue characterization, such as the 
presence or absence of fibrosis, storage diseases and inflammation, and informs on the prognosis, including 
the risk of developing subsequent malignant arrhythmias.32,158-160  
 
4-NEW NOSOLOGICAL FRONTIERS FOR MYOCARDIAL DISEASES: THE MOGE(S) CLASSIFICATION 
SYSTEM 
Myocardial diseases include all those conditions in which the myocardium is not the victim of flow 
restrictions or does not have to adapt to abnormal flow or pressure loads such in valvular or coronary 
disease and hypertension. Integrating morphology as a cornerstone,161 but also deciphering heterogeneity 
regarding organ involvement, genetic predisposition and functional consequences, a new classification 
system for cardiomyopathies called the “MOGES” classification was raised in 2013.162-164 MOGE(S) is 
composed of four main (M, O, G, E) and one optional (S) attributes162-164  and is supported by  a dedicated 
and renewed app that is now linked with the ICD-10 coding system and workable for transfer individual 
data in any sort of database. The five attributes describe the morpho-functional cardiac phenotype (M),165 
the possible involvement of other organs and tissues (O), the genetic or non-genetic origin of the disease 
(G), the specific etiology (E) describing gene and mutation in case of hereditary diseases, or inflammation 
and infectious agents in case of myocarditis, or autoimmune causes or toxic causes in case of non-genetic 
diseases. The S attribute is dynamic and optional: it describes the functional status of the affected heart 
including both NYHA class and AHA stage. The application of MOGE (S) imposes a clinical work-up that 
starts with the phenotypic characterization of the disease and progresses with the investigation of 
involvement of extra-cardiac organs/tissues, the evaluation of the genetic/familial or non-familial disease 
through the clinical screening of the relatives of the patients and the identification, where possible, of the 
causes (Figure 5).  
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Since its first description, MOGE(S) has attracted the attention of experts in cardiomyopathies for possible 
applications in clinical practice: numerous implementations have been proposed to accommodate a 
synthetic but precise description of phenotypes and causes.166-168 In 2015, Hazebroek and colleagues 
integrated multiple etiologic attributes to assess the possible predictive role of their combination on the 
clinical outcome; they observed that familial DCM associated with additional etiologic-environmental 
factors such as significant viral load, immune-mediated factors, rhythm disturbances, or toxic triggers, had 
worse outcome.108 The novelty from their proposal was the idea of applying the MOGE(S) classification to 
assess clinical prognosis and risk stratification in patients with DCM.169 Westphal and coworkers further 
considered those cardiomyopathies whose phenotype may not be unequivocally recognizable by 
echocardiography and highlighted the dynamic level of impairment of the left and/or right ventricular 
systolic (and diastolic) function during the course of myocardial diseases, including baseline and post-
treatment evolution.170 For phenocopies of cardiomyopathies, MOGE(S) describes the possible 
multiorgan/system involvement and summarizes big raw clinical and genetic data, in a short string of 
essential data that can facilitate the collection of large database.171 A similar implementation can be easily 
obtained for genetic cardiomyoapthies.172  Finally, the hypokinetic non-dilated cardiomyopathy (HNDC) 
recently proposed by the Working Group on Myocardial and Pericardial Diseases of the ESC perfectly fits 
with the need of describing the increasingly recognized probands’ relatives presenting with early 
phenotypes in familial DCM.7 Based on the same need of describing early phases of the disease, the recent 
guidelines for HCM of the ESC first introduced the concept of early diagnosis that applies to relatives of 
probands with HCM, when the maximal LV thickness is < 15mm.173 MOGE(S) may appear complex, but the 
“complexity” reflects the modern diagnostics of myocardial diseases, providing a uniform tool to describe 
disease heterogeneity beyond a given phenotype, integrating genetic and acquired determinants.164 
 
5. THERAPEUTIC PROSPECTS 
The treatment of a genetic dilated cardiomyopathy will depend on the i. malignancy (or penetrance) of the 
gene mutation, ii. the phenotypic presentation, iii. The underlying molecular mechanisms leading cardiac 
involvement, and iv. the gene-environmental interactions determining the DCM phenotype.  
The penetrance of gene mutations varies upon the different genes. E.g. a lamin A/C mutation is highly 
penetrant, and therefore would rather require gene correction through silencing of the mutated allele. 
SiRNA mediated silencing of the toxic allele may allow treating more malignant gene mutations. In contrast, 
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more benign gene mutations -such as Titin truncating mutations- with a high probability of improvement 
or recovery of cardiac function upon heart failure treatment would not benefit from gene silencing 
strategies. Also the phenotypic presentation of a gene mutation will determine the therapy. Anti-arrhythmic 
therapies are more often to be considered in LMNA or RBM20 gene mutated DCM patients, whereas classical 
heart failure therapy may be sufficient in other more benign genetic DCM cases.  
The underlying molecular mechanisms identified in experimental models and in the cardiac samples of 
genetic DCM results in novel therapeutic approaches. One example is the recently started phase 3 trial using 
p38 MAPK inhibitors in LMNA-related DCM, since loss of functional lamin proteins results in activation of 
the p38 MAPK pathway, and secondary cardiomyocyte apoptosis and interstitial fibrosis.174 In TTNtv 
patients anti-oxidative therapies such as SS-31 or elamipretide could be considered, in view of the extreme 
hyperactivation of mitochondrial oxidative pathways.175 In sarcomeric gene mutated DCM patients, 
interventions on calcium sensitivity may help to improve myofilament force development, and thereby 
prevent cardiomyocyte dysfunction.43 
Finally, the knowledge how gene mutated hearts would react to environmental -additionally acquired 
diseases or hormonal factors during life- factors, may help to guide our therapeutic approach. E.g. TTNtv 
mutated patients do have a benign functional phenotype, but are prone to develop arrhythmias upon 
additional cardiac stress, such as alcohol, chemotherapy or pregnancy. Therefore, an isolated more benign 
gene mutation without additional environmental factors would require more conservative therapeutic 
approach, whereas a more penetrant LMNA mutations in multi-morbid person would require a more 
aggressive medical attitude.  
 
CONCLUSION 
In the last 20 years, growing evidence supported that DCM is the final morpho-functional phenotype for 
various diseases, for which a spectrum of genetic determinants plays either as a causative role (as in case 
of overt familial disease), or acts as disease modulators regarding another condition (like in sporadic cases 
and “acquired” DCM). By combining clinical characteristics, identifying acquired/environmental triggers, 
using multimodal imaging and genetics, disease heterogeneity becomes progressively a clinical reality, 
allowing improved management of those patients and personalized risk stratification. Genetic data provides 
more and more cues to understand the molecular mechanisms underlying this complex disease and its 
heritability. Nevertheless, caution has to be raised as the use of broad genetic screen exposes clinicians to 
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noisy background in DCM, requiring permanent evaluation of variant pathogenicity. Actual data support 
that inheritance is often complex, with many disease modifiers- going from causal diseases (e.g. 
anthracyclines) to modifying co-morbidities (e.g. diabetes) having to be taken into account including other 
genes, epigenetics and lifestyle. Deep molecular comprehension of DCM improves its assessment, and opens 
new avenues for personalized medicine and the development of new therapeutic strategies. 
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LEGENDS TO FIGURES 
Figure 1: Gene-environmental interactions in dilated cardiomyopathies. DCM is a complex 
multifactorial disease related to genetic determinants interfering with environmental factors. 
Figure 2: Interplay between genes and environmental factors in cardiomyopathies. Heart cartoon is 
reproduced from Wilde et al.176 with permission from Nature Publishing Group (permission to be 
requested).   
Figure 3: Cardiomyopathies: from altered calcium sensitivity to disease phenotype. Altered calcium 
sensitivity related to sarcomeric mutations lead to either hypertrophic cardiomyopathy (increased 
calcium sensitivity/tension with lower free cytosolic calcium) or DCM (decreased calcium 
sensitivity/tension with increased free cytosolic calcium).43 Heart cartoons are reproduced from Wilde et 
al.176 with permission from Nature Publishing Group (permission to be requested).  
Figure 4: The interaction between DNA defects and failing of mitochondrial repair systems 
promotes the genesis of mitochondrial DCM. The exposure of cardiomyocytes to ionizing radiation 
(IR), antiblastic drugs, alcohol metabolites and many other sources of DNA damage leads to mutations in 
both mitochondrial and nuclear genes coding for mitochondrial proteins. When the number of gene 
defects overcomes cellular tolerance, mitochondria can recruit a complex pathway of self-repair and 
regeneration. As the above mechanisms fail, defects tend to accumulate further, leading at the end to 
mitochondrial dysfunction.  
Figure 5: Three examples of MOGE(S) application in arrhythmogenic cardiomyopathy (ACM) (A), 
familial DCM (B) and sporadic DCM phenotype caused by chronic myocarditis (C).  The left column 
shows the pedigrees of three families. The right column shows how family members are described by the 
MOGE(S) system including the imaging view of the proband (B) and the pathology features in 
endomyocardial biopsy of the index patient of family C (C).  For arrhythmogenic cardiomyopathy, 
descriptors of the phenotype can detail the combination of major and minor criteria or define family 
members as diagnosed with definite, possible and borderline cardiomyopathy according to the 2010 Task 
Force. For dilated cardiomyopathy, the age dependency of the phenotype explains the absence of clinical 
signs in the two children (IV:1 and IV:5) of the IVth generation. The p.(Arg190Trp) in LMNA is a recurrent, 
highly penetrant, malignant and validated mutation 
(https://www.ncbi.nlm.nih.gov/clinvar/variation/66908/). 
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Table 1: Main Genes in DCM, isolated and syndromic  
 
Gene Symbol Inheritance Cardiomyopathy overlap Clinical characteristics 
Cytoskeletal    
ACTN2 AD HCM  
ANKRD1 AD HCM  
CSRP3 AD HCM  
LDB3 AD HCM, LVNC Myofibrillar myopathy Type 4 
MYPN AD, AR HCM, RCM Frequent overlapping phenotypes, 
Nemaline myopathy type 11 (AR) 
TCAP AD, AR HCM Limb-girdle muscular dystrophy 2G (AR) 
    
TTN  AD, AR HCM, RCM, ARVC Most frequent, early onset myopathy, 
peripartum cardiomyopathy, truncated 
variants with rhythm disorders, limb-
girdle muscular dystrophy 2J (AR) 
VCL AD HCM  
Sarcomeric    
ACTC1 AD HCM, RCM, LVNC Atrial septal defect 
MYBPC3 AD HCM, RCM, LVNC  
MYH7 AD, AR HCM, LVNC Peripheral myopathy 
TNNC1 AD HCM  
TNNI3 AD, AR RCM, HCM  
TNNT2 AD RCM, HCM, LVNC  
TPM1 AD HCM, LVNC  
Conduction disease 
DES AD, AR HCM, RCM  DES deposition, Limb-girdle muscular 
dystrophy 2R (AR), myofibrillar 
myopathy (AR/AD) 
LMNA AD, AR HCM Congenital muscular dystrophy, Emery-
Dreifuss muscular dystrophy, limb-girdle 
muscular dystrophy 1B 
SCN5A AD, AR ARVC Brugada syndrome, sick sinus syndrome 
(AR), LQT3, atrial fibrillation, ventricular 
fibrillation, heart block 
Arrhythmia 
DSC2 AD, AR ARVC Mild palmoplantar keratoderma and 
woolly hair 
DSG2 AD ARVC  
DSP AD, AR ARVC Epidermolysis bullosa, keratodermia, 
wooly hairs 
    
FLNC AD HCM, RCM, ARVC Rhythmic disorders unrelated to LV 
dysfunction, myofibrillar myopathy 5 
PLN AD HCM  
PKP2 AD ARVC  
RBM20 AD  Atrial fibrillation 
RYR2 AD ARVC Catecholaminergic polymorphic 
ventricular tachycardia 
TTN truncated AD HCM, RCM, ARVC  
Mitochondrial    
CTF1 AD, AR   
DNAJC19 AR  3-methylglutaconic aciduria, type V, 
syndromic (DCMA) recurring in some 
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populations (Canadian Hutterite 
population) 
MT-TL1 Mito HCM DCM-like 
evolution 
MELAS 
SDHA AD,AR, Mito  Leigh syndrome (AR/Mito) and 
mitochondrial respiratory chain complex 
II deficiency (AR) 
Metabolic / Neuromuscular 
BAG3 AD RCM Progressive myofibrillar myopathy 
CPT2 AR, AD  Carnitine palmitoyltranferase III 
deficiency 
    
CRYAB AD,AR RCM Myofibrillar myopathy 2 (AR) 
DMD XLR  Duchenne/Becker muscular dystrophy 
DOLK AR   
EMD XLR  Emery-Dreifuss muscular dystrophy 
HADHA AR HCM AR syndromic phenotypes with 
cardiomyopathy 
HFE AR HCM, RCM Iron Overload 
LAMP2 XLD HCM Danon Disease 
SGCD AD, AR  Limb-girdle muscular dystrophy (delta-
sarcoglycanopathy) 
SLC22A5 AR HCM Carnitine deficiency 
SYNE1 AD, AR  Emery-Dreifuss muscular dystrophy 
(AD), Spinocerebellar ataxia (AR) 
TAZ XLR  Endocardial fibroelastosis, BARTH 
Syndrome 
TMPO AD  Reclassified as non-pathogenic 
Others 
EYA4 AD  Non-syndromic hearing loss and 
deafness 
GATAD1 AR   
NEXN AD HCM  
PSEN1 AD  Familial Alzheimer disease 
PSEN2 AD  Familial Alzheimer disease 
 
Genes presenting a statistically significant excess burden over controls in Exac are depicted in bold.10 Figure 
content is adapted from Burke et al9 and Lee et al10. 
AD: autosomal dominant; AR: autosomal recessive; ARVC: arrhythmogenic right ventricular cardiomyopathy; 
DCM: dilated cardiomyopathy; HCM: hypertrophic cardiomyopathy; LVNC: left ventricular non-compaction; 
Mito: mitochondrial; RCM: restrictive cardiomyopathy; XLD: X-linked dominant; XLR: X-linked recessive. 
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Acquired diseases/
Environmental 
(toxic, pregnancy, hypertension
diabetes, tachycardia, …)
(Mono)-genetic
DCM phenotype: gene-environmental interaction
e.g.  Lamin A/C
Phospholamban
RBM-20
e.g. Titin tve.g. MyH7
Bondue et al. Figure 1
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